The Blackstone Group L.P. (BX) continued its downward trend with the stock declining -1.31% or $-0.4 to close the day at $30.07 on active trading volume of 5.26M shares, compared to its three month average trading volume of 5.02M. The New York New York 10154 based company has been outperforming the asset management group over the past 52 weeks, with the stock gaining 29.95%, compared to the industry which has advanced 25.59% over the same period. With RSI of 65.97, the stock should still continue to rise and get closer to its one year target estimate of $32.92, making it a hold for now.
The Blackstone Group L.P. is a publicly owned hedge fund sponsor. The firm also provides financial advisory services to its clients. It provides its services to public and corporate pension funds, academic, cultural, and charitable organizations, retirees, sovereign wealth funds, and institutional and individual investors. The firm manages separate client focused portfolios for its clients. It launches fixed income mutual funds. The firm also launches and manages private equity funds, real estate funds, funds of hedge funds, and credit-focused funds for its clients. It invests in private equity, public equity, fixed income, and alternative investment markets. The Blackstone Group L.P. was founded in 1985 and is based in New York, New York with additional offices in London, United Kingdom, Hong Kong, Beijing, China, Dubai, UAE, Dusseldorf, Germany, Los Angeles, Santa Monica, Mexico City, Mexico, Paris, France, Sao Paulo, Brazil, Seoul, Korea, Shanghai, China, Singapore, Sydney, Australia, Copenhagen, Denmark, and Tokyo, Japan.
AMAG Pharmaceuticals, Inc. (AMAG) grew with the stock adding 0.43% or $0.1 to close at $23.1 on active trading volume of 5.26M compared its three months average trading volume of 1.09M. The Waltham Massachusetts 02451 based company operating under the Diagnostic Substances industry has been trending down for the last 52 weeks, with the shares price now -1.07% down for the period and down by -33.62% so far this year. With price target of $37.4 and a 28.91% rebound from 52-week low, AMAG Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.
AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units. In addition, it has a license agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Fifth Third Bancorp (FITB) managed to rebound with the stock climbing 1.16% or $0.31 to close the day at $27.07 on lower than average trading volume of 5.24M shares, compared to its three month average trading volume of 7.76M. The Cincinnati Ohio 45263 based company has been outperforming the regional – midwest banks companies by 31.3246% for last three months and its recent gains have pushed the stock slightly up 0.37% YTD, versus the regional – midwest banks industry which is down -0.22% for the same period. The RSI of 57.56 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Fifth Third Bancorp operates as a diversified financial services company in the United States. It operates through four segments: Commercial Banking, Branch Banking, Consumer Lending, and Investment Advisors. The Commercial Banking segment offers credit intermediation, cash management, and financial services; lending and depository products; and foreign exchange and international trade finance, derivatives and capital markets services, asset-based lending, real estate finance, public finance, commercial leasing, and syndicated finance for business, government, and professional customers. The Branch Banking segment provides deposit and loan products to individuals and small businesses. This segment offers checking and savings accounts, home equity loans and lines of credit, credit cards, and loans for automobiles and personal financing needs. The Consumer Lending segment engages in direct lending activities that include origination, retention, and servicing of residential mortgage and home equity loans or lines of credit; and indirect lending activities, including loans to consumers through correspondent lenders and automobile dealers. The Investment Advisors segment provides various investment alternatives for individuals, companies, and not-for-profit organizations. It offers retail brokerage services to individual clients; and broker dealer services to the institutional marketplace. This segment also provides asset management services; holistic strategies to affluent clients in wealth planning, investing, insurance, and wealth protection; and advisory services for institutional clients comprising states and municipalities. As of December 31, 2015, the company operated 1,254 full-service banking centers, including 95 Bank Mart locations, as well as 2,593 automated teller machines in 12 states throughout the Midwestern and Southeastern regions of the United States. Fifth Third Bancorp was founded in 1862 and is headquartered in Cincinnati, Ohio.